Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Mayne Pharma Group Limited stock logo
MAYNF
Mayne Pharma Group
$3.33
$3.51
$2.42
$4.60
N/AN/A2,179 shsN/A
Otsuka Holdings Co., Ltd. - Unsponsored ADR stock logo
OTSKY
Otsuka
$23.57
-1.5%
$24.29
$21.17
$32.41
$25.32BN/A45,916 shs16,169 shs
Roche Holding AG stock logo
RHHVF
Roche
$320.40
-2.9%
$320.78
$267.55
$354.19
N/AN/A7,962 shs25,205 shs
Sanofi stock logo
SNYNF
Sanofi
$98.33
+1.7%
$101.42
$91.81
$122.03
N/AN/A21,200 shs327 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Mayne Pharma Group Limited stock logo
MAYNF
Mayne Pharma Group
0.00%0.00%+7.95%-20.42%+11.01%
Otsuka Holdings Co., Ltd. - Unsponsored ADR stock logo
OTSKY
Otsuka
0.00%-4.84%-2.56%-5.76%+10.42%
Roche Holding AG stock logo
RHHVF
Roche
0.00%-0.99%-2.74%+6.09%+17.65%
Sanofi stock logo
SNYNF
Sanofi
0.00%+0.97%+1.32%-5.43%+3.02%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Mayne Pharma Group Limited stock logo
MAYNF
Mayne Pharma Group
0.1107 of 5 stars
0.03.00.00.00.90.00.0
Otsuka Holdings Co., Ltd. - Unsponsored ADR stock logo
OTSKY
Otsuka
N/AN/AN/AN/AN/AN/AN/AN/A
Roche Holding AG stock logo
RHHVF
Roche
0.0419 of 5 stars
0.01.01.70.00.00.00.0
Sanofi stock logo
SNYNF
Sanofi
0.8336 of 5 stars
0.02.01.74.01.30.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Mayne Pharma Group Limited stock logo
MAYNF
Mayne Pharma Group
0.00
N/AN/AN/A
Otsuka Holdings Co., Ltd. - Unsponsored ADR stock logo
OTSKY
Otsuka
0.00
N/AN/AN/A
Roche Holding AG stock logo
RHHVF
Roche
0.00
N/AN/AN/A
Sanofi stock logo
SNYNF
Sanofi
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Mayne Pharma Group Limited stock logo
MAYNF
Mayne Pharma Group
N/AN/AN/AN/AN/AN/A
Otsuka Holdings Co., Ltd. - Unsponsored ADR stock logo
OTSKY
Otsuka
N/AN/AN/AN/AN/AN/A
Roche Holding AG stock logo
RHHVF
Roche
N/AN/AN/AN/AN/AN/A
Sanofi stock logo
SNYNF
Sanofi
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Mayne Pharma Group Limited stock logo
MAYNF
Mayne Pharma Group
N/A$0.0492.51N/AN/AN/AN/A8/20/2025 (Estimated)
Otsuka Holdings Co., Ltd. - Unsponsored ADR stock logo
OTSKY
Otsuka
N/A$150.910.16N/AN/AN/AN/A7/29/2025 (Estimated)
Roche Holding AG stock logo
RHHVF
Roche
N/A$10.8129.64N/AN/AN/AN/A7/24/2025 (Estimated)
Sanofi stock logo
SNYNF
Sanofi
N/A$3.0831.88N/AN/AN/AN/A7/31/2025 (Estimated)
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Mayne Pharma Group Limited stock logo
MAYNF
Mayne Pharma Group
N/AN/AN/AN/AN/A
Otsuka Holdings Co., Ltd. - Unsponsored ADR stock logo
OTSKY
Otsuka
N/AN/AN/AN/AN/A
Roche Holding AG stock logo
RHHVF
Roche
$7.802.43%N/A72.16%N/A
Sanofi stock logo
SNYNF
Sanofi
$2.802.85%N/A90.78%N/A

Institutional Ownership

CompanyInstitutional Ownership
Mayne Pharma Group Limited stock logo
MAYNF
Mayne Pharma Group
15.80%
Otsuka Holdings Co., Ltd. - Unsponsored ADR stock logo
OTSKY
Otsuka
N/A
Roche Holding AG stock logo
RHHVF
Roche
29.01%
Sanofi stock logo
SNYNF
Sanofi
30.06%

Insider Ownership

CompanyInsider Ownership
Mayne Pharma Group Limited stock logo
MAYNF
Mayne Pharma Group
N/A
Otsuka Holdings Co., Ltd. - Unsponsored ADR stock logo
OTSKY
Otsuka
N/A
Roche Holding AG stock logo
RHHVF
Roche
N/A
Sanofi stock logo
SNYNF
Sanofi
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Mayne Pharma Group Limited stock logo
MAYNF
Mayne Pharma Group
780N/AN/ANot Optionable
Otsuka Holdings Co., Ltd. - Unsponsored ADR stock logo
OTSKY
Otsuka
34,3881.07 billionN/ANot Optionable
Roche Holding AG stock logo
RHHVF
Roche
103,605N/AN/ANot Optionable
Sanofi stock logo
SNYNF
Sanofi
91,600N/AN/ANot Optionable

Recent News About These Companies

Sanofi (SAN.PA)
Sanofi (SNYNF) Gets a Buy from Berenberg Bank
Guggenheim Reaffirms Their Buy Rating on Sanofi (SNYNF)
Sanofi (SNYNF) Gets a Hold from Deutsche Bank
J.P. Morgan Keeps Their Hold Rating on Sanofi (SNYNF)
Goldman Sachs Reaffirms Their Hold Rating on Sanofi (SNYNF)
Barclays Keeps Their Buy Rating on Sanofi (SNYNF)

Media Sentiment Over Time

Mayne Pharma Group stock logo

Mayne Pharma Group OTCMKTS:MAYNF

$3.33 0.00 (0.00%)
As of 07/3/2025

Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. The company operates through four segments: International Branded Products, and Portfolio Product Division. It provides oral drug delivery systems; and contract development and manufacturing services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.

Otsuka stock logo

Otsuka OTCMKTS:OTSKY

$23.57 -0.36 (-1.50%)
As of 07/3/2025 12:50 PM Eastern

Otsuka Holdings Co., Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. The company develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, digestive system, ophthalmology, and diagnostics, as well as intravenous solutions and medical devices. It also provides clinical testing, medical equipment, food products, cosmetics, functional food products, chemical products, soft drinks, beverages, analytical and measurement instruments, nutritional products, vehicle headlight testers, synthetic resin molded products, paper products, and insecticide and toiletry products. In addition, the company offers IT solution services; adhesive tapes; flaky titanate and compounds; IV solutions; infusion and clinical nutrition products; hydrazine; plant-based food products; reinsurance underwriting services; wine; stable isotopes; food supplements; urinary tract health products; software and services for management of mental healthcare systems; anticancer drugs; terracess; bio-pesticides; dietetic food products; spring and mineral water; and polyolefin foams. Further, it engages in the warehousing and transport, medical device operational management, shared service, environmental health management, and venture capital and incubation businesses; rental of medical devices and related products; purchase and sale of agricultural products; import and export trading business; tuberculosis research and development activities; manufacturing and development of xenotransplantation products; and processing and marketing of functional films, as well as planning, design, production, and construction of ceramic boards and arts, ceramic walls, reliefs, terracotta, ceramic OT and portraits, and ceramic sign boards; and operation of travel agency, and Hotel Ridge and California Table. Otsuka Holdings Co., Ltd. was founded in 1921 and is headquartered in Tokyo, Japan.

Roche stock logo

Roche OTCMKTS:RHHVF

$320.40 -9.60 (-2.91%)
As of 07/3/2025 12:12 PM Eastern

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.

Sanofi stock logo

Sanofi OTCMKTS:SNYNF

$98.33 +1.68 (+1.74%)
As of 07/3/2025 10:53 AM Eastern

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.